Capital Analysts LLC’s Thermo Fisher Scientific TMO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $3.35M | Sell |
6,670
-231
| -3% | -$111K | 0.08% | 201 |
|
|
2026
Q1 | $3.39M | Sell |
6,901
-522
| -7% | -$283K | 0.09% | 186 |
|
|
2025
Q4 | $4.3M | Sell |
7,423
-101
| -1% | -$57.1K | 0.12% | 149 |
|
|
2025
Q3 | $3.65M | Buy |
7,524
+534
| +8% | +$249K | 0.11% | 169 |
|
|
2025
Q2 | $2.83M | Buy |
6,990
+255
| +4% | +$107K | 0.09% | 173 |
|
|
2025
Q1 | $3.35M | Buy |
6,735
+598
| +10% | +$324K | 0.13% | 147 |
|
|
2024
Q4 | $3.19M | Buy |
6,137
+599
| +11% | +$329K | 0.13% | 136 |
|
|
2024
Q3 | $3.43M | Buy |
5,538
+592
| +12% | +$350K | 0.14% | 128 |
|
|
2024
Q2 | $2.74M | Buy |
4,946
+459
| +10% | +$263K | 0.12% | 145 |
|
|
2024
Q1 | $2.61M | Sell |
4,487
-25
| -0.6% | -$14K | 0.12% | 142 |
|
|
2023
Q4 | $2.4M | Sell |
4,512
-162
| -3% | -$78.4K | 0.12% | 143 |
|
|
2023
Q3 | $2.37M | Buy |
4,674
+38
| +0.8% | +$20.2K | 0.13% | 132 |
|
|
2023
Q2 | $2.42M | Sell |
4,636
-42
| -0.9% | -$22.7K | 0.13% | 134 |
|
|
2023
Q1 | $2.7M | Sell |
4,678
-86
| -2% | -$48.5K | 0.15% | 122 |
|
|
2022
Q4 | $2.62M | Sell |
4,764
-138
| -3% | -$73.1K | 0.16% | 124 |
|
|
2022
Q3 | $2.49M | Sell |
4,902
-26
| -0.5% | -$14.6K | 0.17% | 121 |
|
|
2022
Q2 | $2.68M | Buy |
4,928
+43
| +0.9% | +$23.7K | 0.19% | 113 |
|
|
2022
Q1 | $2.89M | Buy |
4,885
+81
| +2% | +$46.5K | 0.18% | 118 |
|
|
2021
Q4 | $3.21M | Buy |
4,804
+26
| +0.5% | +$16.2K | 0.19% | 106 |
|
|
2021
Q3 | $2.73M | Buy |
4,778
+355
| +8% | +$195K | 0.18% | 117 |
|
|
2021
Q2 | $2.23M | Sell |
4,423
-18
| -0.4% | -$8.49K | 0.15% | 136 |
|
|
2021
Q1 | $2.03M | Buy |
4,441
+747
| +20% | +$357K | 0.14% | 132 |
|
|
2020
Q4 | $1.72M | Sell |
3,694
-1,035
| -22% | -$485K | 0.15% | 118 |
|
|
2020
Q3 | $2.09M | Buy |
4,729
+517
| +12% | +$214K | 0.2% | 94 |
|
|
2020
Q2 | $1.53M | Sell |
4,212
-408
| -9% | -$137K | 0.16% | 121 |
|
|
2020
Q1 | $1.31M | Sell |
4,620
-176
| -4% | -$55.5K | 0.16% | 113 |
|
|
2019
Q4 | $1.56M | Buy |
4,796
+164
| +4% | +$49.7K | 0.15% | 128 |
|
|
2019
Q3 | $1.35M | Buy |
4,632
+335
| +8% | +$95.9K | 0.14% | 135 |
|
|
2019
Q2 | $1.26M | Sell |
4,297
-329
| -7% | -$90.6K | 0.14% | 140 |
|
|
2019
Q1 | $1.27M | Sell |
4,626
-1,069
| -19% | -$266K | 0.15% | 128 |
|
|
2018
Q4 | $1.27M | Sell |
5,695
-285
| -5% | -$66.9K | 0.17% | 106 |
|
|
2018
Q3 | $1.46M | Buy |
5,980
+156
| +3% | +$35.9K | 0.17% | 108 |
|
|
2018
Q2 | $1.21M | Sell |
5,824
-35
| -0.6% | -$7.43K | 0.14% | 118 |
|
|
2018
Q1 | $1.21M | Buy |
5,859
+209
| +4% | +$43.9K | 0.15% | 111 |
|
|
2017
Q4 | $1.07M | Buy |
5,650
+295
| +6% | +$56.5K | 0.13% | 134 |
|
|
2017
Q3 | $1.01M | Buy |
5,355
+143
| +3% | +$25.9K | 0.14% | 124 |
|
|
2017
Q2 | $909K | Sell |
5,212
-10
| -0.2% | -$1.68K | 0.13% | 129 |
|
|
2017
Q1 | $802K | Buy |
5,222
+565
| +12% | +$86.4K | 0.13% | 122 |
|
|
2016
Q4 | $657K | Buy |
4,657
+157
| +3% | +$23.1K | 0.12% | 129 |
|
|
2016
Q3 | $716K | Sell |
4,500
-59
| -1% | -$9.09K | 0.13% | 114 |
|
|
2016
Q2 | $674K | Sell |
4,559
-31
| -0.7% | -$4.58K | 0.14% | 118 |
|
|
2016
Q1 | $650K | Buy |
4,590
+216
| +5% | +$28.9K | 0.13% | 125 |
|
|
2015
Q4 | $620K | Buy |
+4,374
| New | +$583K | 0.13% | 127 |
|
Other funds holding TMO
Capital Analysts LLC's TMO Position: Q2 2026 in Review
Capital Analysts LLC reduced its Thermo Fisher Scientific (TMO) stake by 3.3% in Q2 2026, selling an estimated $111K and leaving 6,670 shares worth $3.35M. The position accounts for 0.08% of the portfolio, ranked #201.
Capital Analysts LLC first reported a position in TMO in Q4 2015 and has held it in 43 quarters since. The position peaked at $4.3M in Q4 2025. 2,609 funds tracked by Wall St. Rank hold TMO as of Q2 2026.
- Capital Analysts LLC held 6,670 shares of Thermo Fisher Scientific worth $3.35M as of Q2 2026.
- Capital Analysts LLC sold 231 Thermo Fisher Scientific shares in Q2 2026, an estimated $111K.
- Thermo Fisher Scientific made up 0.08% of Capital Analysts LLC's portfolio in Q2 2026, its #201 holding.
- Capital Analysts LLC first reported a position in Thermo Fisher Scientific in Q4 2015 and has held it in 43 quarters since.
- Capital Analysts LLC's Thermo Fisher Scientific position peaked at $4.3M in Q4 2025.
- 2,609 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q2 2026.
Based on Capital Analysts LLC's 13F filing for Q2 2026, filed 5 Aug 2026.